Needham analyst David Saxon maintained a Hold rating on ZimVie Inc (ZIMV – Research Report) today. The company’s shares closed yesterday at $19.60.
According to TipRanks, Saxon is a 4-star analyst with an average return of 7.5% and a 44.12% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Glaukos, and SI-Bone.
Currently, the analyst consensus on ZimVie Inc is a Moderate Sell with an average price target of $14.50.
See the top stocks recommended by analysts >>
The company has a one-year high of $20.91 and a one-year low of $5.05. Currently, ZimVie Inc has an average volume of 394.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ZimVie Inc (ZIMV) Company Description:
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions.
Read More on ZIMV:
- ZimVie Inc Enhances Transparency with Supplementary Financial Data
- ZimVie to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
- ZimVie launches TSX Implant in Japan
- ZimVie Announces Launch of Next-Generation TSX® Implant in Japan
- ZimVie price target raised to $13 from $11 at Barclays
